ATE160821T1 - Nukleinsäureliganden - Google Patents

Nukleinsäureliganden

Info

Publication number
ATE160821T1
ATE160821T1 AT91912753T AT91912753T ATE160821T1 AT E160821 T1 ATE160821 T1 AT E160821T1 AT 91912753 T AT91912753 T AT 91912753T AT 91912753 T AT91912753 T AT 91912753T AT E160821 T1 ATE160821 T1 AT E160821T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid ligands
nucleic acids
referred
ligands
Prior art date
Application number
AT91912753T
Other languages
English (en)
Inventor
Larry Gold
Craig Tuerk
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24138463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE160821(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE160821T1 publication Critical patent/ATE160821T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G01N2333/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96436—Granzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/966—Elastase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9726—Tissue plasminogen activator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
AT91912753T 1990-06-11 1991-06-10 Nukleinsäureliganden ATE160821T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53642890A 1990-06-11 1990-06-11

Publications (1)

Publication Number Publication Date
ATE160821T1 true ATE160821T1 (de) 1997-12-15

Family

ID=24138463

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91912753T ATE160821T1 (de) 1990-06-11 1991-06-10 Nukleinsäureliganden
AT97200035T ATE318832T1 (de) 1990-06-11 1991-06-10 Verfahren zur vervendung von nukleinsäureliganden

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97200035T ATE318832T1 (de) 1990-06-11 1991-06-10 Verfahren zur vervendung von nukleinsäureliganden

Country Status (16)

Country Link
US (8) US5475096A (de)
EP (4) EP1493825A3 (de)
JP (4) JP2763958B2 (de)
KR (1) KR970002255B1 (de)
AT (2) ATE160821T1 (de)
AU (1) AU663053B2 (de)
CA (1) CA2084987C (de)
DE (2) DE69128350T2 (de)
DK (2) DK0786469T3 (de)
ES (2) ES2110444T3 (de)
GR (1) GR3025594T3 (de)
IE (1) IE911979A1 (de)
IL (2) IL98456A (de)
NZ (1) NZ238492A (de)
RU (1) RU2198931C2 (de)
WO (1) WO1991019813A1 (de)

Families Citing this family (982)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US6716580B2 (en) * 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6759392B1 (en) * 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US6261774B1 (en) * 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5972599A (en) 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
JPH06503715A (ja) * 1990-09-21 1994-04-28 フレッド ハッチンソン キャンサー リサーチ センター タンパク質配列特異的オリゴヌクレオチド配列
JPH06508022A (ja) * 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU2580892A (en) * 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
WO1993014108A1 (en) * 1992-01-13 1993-07-22 President And Fellows Of Harvard College Selection of binding-molecules
US5783384A (en) * 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US6582902B1 (en) 1992-09-30 2003-06-24 Jack D. Keene Method for deriving epitopes
AU4842693A (en) * 1992-09-11 1994-04-12 Duke University Method for deriving epitopes
DE69333961T2 (de) * 1992-09-29 2006-08-24 Gilead Sciences, Inc., Foster City Nukleinsäureliganden und ihre herstellungsmethoden
WO1994009158A1 (en) * 1992-10-14 1994-04-28 University Research Corporation Method for selecting nucleic acids on the basis of structure
JPH09502354A (ja) * 1993-09-08 1997-03-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンドと、同リガンドを製造するための改良された方法
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
AU692185B2 (en) * 1993-09-17 1998-06-04 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6458539B1 (en) * 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
CA2179315A1 (en) * 1993-12-17 1995-06-22 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
GB9401833D0 (en) * 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US20020077306A1 (en) * 1994-07-14 2002-06-20 Ludger Dinkelborg Conjugates made of metal complexes and oligonucleotides, agents containing the conjugates, their use in radiodiagnosis as well as process for their production
IL114237A (en) * 1994-07-14 2000-08-31 Schering Ag Oligonucleotide conjugates and diagnostic processes utilizing the same
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5663064A (en) * 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
WO1996027604A1 (en) * 1995-03-06 1996-09-12 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
AU727460B2 (en) 1995-05-03 2000-12-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
AU732961B2 (en) * 1995-05-03 2001-05-03 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
AU728176B2 (en) * 1995-05-04 2001-01-04 Gilead Sciences, Inc. Nucleic acid ligand complexes
JP5637528B2 (ja) * 1995-05-04 2014-12-10 ギリード・サイエンシズ・インコーポレーテッド 核酸リガンド複合体
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
DK2080813T3 (da) 1995-06-07 2011-03-28 Gilead Sciences Inc Nukleinsyreligander, som binder til og inhiberer DNA-polymeraser
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
US20020106647A1 (en) * 1996-07-24 2002-08-08 Segal Andrew H. Nucleic acid compositions and methods of introducing nucleic acids into cells
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP2319854B1 (de) 1997-01-08 2016-11-30 Sigma-Aldrich Co. LLC Biokonjugation von Makromolekülen
WO1998032880A1 (en) 1997-01-23 1998-07-30 Immusol Incorporated Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries
WO1999067423A1 (en) * 1998-06-22 1999-12-29 The Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US5834199A (en) * 1997-04-29 1998-11-10 North Carolina State University Methods of identifying transition metal complexes that selectively cleave regulatory elements of mRNA and uses thereof
CA2220785A1 (en) * 1997-12-02 1999-06-02 Noureddine Rouissi Selective technique for rapid identification of proteins and genes and uses thereof
WO1999031276A1 (en) 1997-12-15 1999-06-24 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20070166741A1 (en) * 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6268131B1 (en) 1997-12-15 2001-07-31 Sequenom, Inc. Mass spectrometric methods for sequencing nucleic acids
US20060057573A1 (en) * 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6441158B1 (en) 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
DE19800899A1 (de) * 1998-01-13 1999-07-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Oligoliganden mit Bindungsvermögen etc.
US6537747B1 (en) 1998-02-03 2003-03-25 Lucent Technologies Inc. Data transmission using DNA oligomers
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6225063B1 (en) 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
EP1090293B2 (de) 1998-06-24 2019-01-23 Illumina, Inc. Dekodierung von matrixartig-angeordneten Sensoren durch Mikropartikel
US6100035A (en) 1998-07-14 2000-08-08 Cistem Molecular Corporation Method of identifying cis acting nucleic acid elements
US20040259079A1 (en) * 1998-07-22 2004-12-23 Immusol, Inc. Substantially complete ribozyme libraries
WO2000011446A2 (en) * 1998-08-21 2000-03-02 University Of Virginia Patent Foundation Signal generating oligonucleotide-based biosensor
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
EP1002875A1 (de) * 1998-11-17 2000-05-24 Mira Diagnostica GmbH Oligonucleotid Inhibitor von thermostabilen Polymerasen
US6927024B2 (en) * 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US6858390B2 (en) * 1998-12-31 2005-02-22 Ingeneus Corporation Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
CA2259745A1 (en) * 1999-01-19 2000-07-19 Guy Tremblay Generation of oligonucleotide libraries representative of genomes or expressed mrnas (cdnas) and use thereof
WO2000043534A1 (en) * 1999-01-19 2000-07-27 Somalogic, Inc. Method and apparatus for the automated generation of nucleic acid ligands
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US7189506B1 (en) 1999-03-03 2007-03-13 Genelabs Technologies, Inc. DNA binding compound-mediated molecular switch system
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
EP1923471B1 (de) 1999-04-20 2012-12-19 Illumina, Inc. Erkennung von Nukleinsäurereaktionen auf Bead-Arrays
US20030207295A1 (en) * 1999-04-20 2003-11-06 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
US6680377B1 (en) 1999-05-14 2004-01-20 Brandeis University Nucleic acid-based detection
US8080380B2 (en) 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8481268B2 (en) 1999-05-21 2013-07-09 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US7074586B1 (en) 1999-06-17 2006-07-11 Source Precision Medicine, Inc. Quantitative assay for low abundance molecules
WO2001006249A2 (en) 1999-07-02 2001-01-25 Conceptual Mindworks, Inc. Organic semiconductor recognition complex and system
US6387620B1 (en) * 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US6506887B1 (en) * 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
MXPA00008256A (es) * 1999-08-26 2002-04-24 Antonio Santa Coloma Tomas Oligocuerpos policlonales y monoclonales(reactivos sinteticos tipo anticuerpo basados en oligonucleotido), y un metodo para producir oligocuerpos.
CA2391433C (en) 1999-11-24 2011-02-08 The Research Foundation Of State University Of New York Catalytic rnas with aminoacylation activity
US6558911B1 (en) 1999-12-10 2003-05-06 Oregon Health Sciences University Sperm quality assay
CA2328356A1 (en) 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
US20010039015A1 (en) * 2000-01-21 2001-11-08 Edward Sauter Nipple aspirate fluid specific microarrays
EP1257668B1 (de) 2000-02-16 2008-10-29 Illumina, Inc. Parallele genotypisierung mehrerer patientenproben
EP2365096A1 (de) 2000-03-22 2011-09-14 Life Technologies Corporation Verfahren zur Verwendung von Halbleiternanokristallen in Nukleinsäureassays auf Kügelchenbasis
US7129326B2 (en) * 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
US20020098524A1 (en) * 2000-04-14 2002-07-25 Murray Christopher J. Methods for selective targeting
US7682837B2 (en) * 2000-05-05 2010-03-23 Board Of Trustees Of Leland Stanford Junior University Devices and methods to form a randomly ordered array of magnetic beads and uses thereof
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US7892484B2 (en) * 2000-06-30 2011-02-22 Conceptual Mindworks, Inc. Methods and compositions for neutralizing anthrax and other bioagents
US20030207271A1 (en) * 2000-06-30 2003-11-06 Holwitt Eric A. Methods and compositions for biological sensors
WO2002006827A1 (en) * 2000-07-05 2002-01-24 The General Hospital Corporation Compounds and methods for fluorescently labeling nucleic acids
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP2322648A1 (de) 2000-09-26 2011-05-18 Duke University RNA-Aptamere und Verfahren zu ihrer Identifizierung
DE10049074A1 (de) * 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
DE10048944A1 (de) * 2000-10-03 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren durch zweidimensionale Auftrennung
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
ATE425457T1 (de) 2000-10-06 2009-03-15 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
CA2425605A1 (en) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US20050054942A1 (en) 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
JP4379561B2 (ja) * 2001-01-30 2009-12-09 キヤノンファインテック株式会社 シート処理装置及びこれを備えた画像形成装置
US7115369B2 (en) * 2001-03-15 2006-10-03 Iowa State University Research Foundation, Inc. Functional nucleic acid probes and uses thereof
AU2002257076A1 (en) 2001-03-19 2002-10-03 President And Fellows Of Harvard College Nucleic acid shuffling
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
CA2442092A1 (en) * 2001-03-26 2002-10-17 Ribozyme Pharmaceuticals, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
DE10122847A1 (de) * 2001-05-11 2002-11-21 Noxxon Pharma Ag Enterotoxin B bindende Nukleinsäure
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20030124513A1 (en) * 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
DK1401853T3 (da) * 2001-05-25 2010-11-01 Univ Duke Modulatorer af farmakologiske midler
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
CN1604795B (zh) 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
JP2005500058A (ja) 2001-08-17 2005-01-06 ネオーズ テクノロジーズ， インコーポレイテッド シアリル化したオリゴサッカリドの化学的酵素的合成
WO2003029492A1 (en) * 2001-09-28 2003-04-10 Justin Gallivan Metabolic genes and related methods and compositions
AU2002365084A1 (en) * 2001-10-19 2003-07-24 Sirna Therapeutics, Inc Method and reagent for the detection of proteins and peptides
FI115343B (fi) * 2001-10-22 2005-04-15 Filtronic Lk Oy Sisäinen monikaista-antenni
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
US20030162190A1 (en) * 2001-11-15 2003-08-28 Gorenstein David G. Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics
ATE414767T1 (de) 2001-11-22 2008-12-15 Sloning Biotechnology Gmbh Nukleinsäure-linker und deren verwendung in der gensynthese
US20030219775A1 (en) * 2001-12-14 2003-11-27 Ward David C. Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
WO2003051314A2 (en) 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US20040002083A1 (en) * 2002-01-29 2004-01-01 Ye Ding Statistical algorithms for folding and target accessibility prediction and design of nucleic acids
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
AU2003215240A1 (en) * 2002-02-14 2003-09-04 Illumina, Inc. Automated information processing in randomly ordered arrays
US7622248B2 (en) * 2002-02-15 2009-11-24 The Research Foundation Of State University Of New York Ribozymes with broad tRNA aminoacylation activity
AU2003217580A1 (en) * 2002-02-19 2003-09-09 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003213729A1 (en) 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Biospecific contrast agents
US20030219801A1 (en) * 2002-03-06 2003-11-27 Affymetrix, Inc. Aptamer base technique for ligand identification
US20040018515A1 (en) * 2002-04-03 2004-01-29 Diener John L. Compositions selective for adenosine diphosphate and methods of using same
AU2003233243A1 (en) * 2002-05-06 2003-11-17 Noxxon Pharma Ag Method for amplifying nucleic acids
KR101083450B1 (ko) 2002-05-27 2011-11-16 페르 손네 홀름 아데노바이러스 및 그를 코딩하는 핵산의 신규 용도
AU2003238772A1 (en) * 2002-05-31 2003-12-19 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US6989442B2 (en) * 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US7655790B2 (en) * 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
JP2005533862A (ja) * 2002-07-25 2005-11-10 アーケミックス コーポレイション 調節されたアプタマー治療剤
WO2004013274A2 (en) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
CN1674929B (zh) 2002-08-14 2013-07-17 赛伦斯治疗公司 蛋白激酶Nβ的应用
EP1393742A1 (de) 2002-08-14 2004-03-03 atugen AG Verwendung von Protein Kinase N beta
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
DE10241938A1 (de) * 2002-09-10 2004-03-25 Noxxon Pharma Ag Verfahren zur Selektion von Nukleinsäureliganden
EP2348317B1 (de) 2002-09-11 2014-12-03 University Of Florida Research Foundation, Inc. Erkennen eines Schädel-Hirn Traumas mit Hilfe von Alpha II Spektrin Abbauprodukten (SBDP)
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
EP1546170A4 (de) * 2002-09-20 2007-08-29 Univ Yale Riboswitche, verfahren zu deren anwendung und zusammensetzungen, die mit riboswitchen verwendet werden
US20040110213A1 (en) * 2002-09-30 2004-06-10 Eugeni Namsaraev Polynucleotide synthesis and labeling by kinetic sampling ligation
EP1551869A2 (de) 2002-10-15 2005-07-13 Intercell AG Bindungdsfaktoren von gruppe b-streptococcus, dafür kodierende nukleinsäuren und verwendungen davon
CA2502610A1 (en) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
DE60325754D1 (de) 2002-10-18 2009-02-26 Silence Therapeutics Ag An der metastase beteiligter faktor und verwendungen dafür
GB0225833D0 (en) * 2002-11-06 2002-12-11 Univ Leeds Nucleic acid ligands and uses therefor
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
AU2003297557B2 (en) 2002-11-21 2009-02-26 Cellscript, Inc. Methods for using primers that encode one strand of a double-stranded promoter
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2004047742A2 (en) * 2002-11-21 2004-06-10 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2006514932A (ja) 2002-11-25 2006-05-18 ジェネンコー・インターナショナル・インク 皮膚、または髪に結合するペプチド
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1578954A4 (de) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-cpg-nukleinsäuren und verwendungsverfahren
US6936496B2 (en) * 2002-12-20 2005-08-30 Hewlett-Packard Development Company, L.P. Nanowire filament
WO2004060791A1 (en) * 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US6943768B2 (en) 2003-02-21 2005-09-13 Xtellus Inc. Thermal control system for liquid crystal cell
US6861251B2 (en) 2003-02-24 2005-03-01 Pritest, Inc. Translucent solid matrix assay device for microarray analysis
DE602004028445D1 (de) * 2003-02-24 2010-09-16 Pritest Inc Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
WO2004078907A2 (en) 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens
US7140685B2 (en) * 2003-03-11 2006-11-28 Gardner Kenneth J Swivel chair joint
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
CA2520846C (en) 2003-03-31 2013-09-24 Mcmaster University Aptamer selection method
EP2182065A3 (de) 2003-03-31 2010-09-15 Intercell AG Staphylococcus epidermidis Antigene
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
EP2333114A1 (de) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae Antigene
EP1620547B1 (de) 2003-04-21 2014-06-18 Archemix LLC Stabilisierte aptamere für blutplättchen-wachstumsfaktor und ihre verwendung als onkologietherapeutika
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
WO2004099411A1 (en) * 2003-05-07 2004-11-18 Novartis Ag A method for dissecting the rna secondary structure dependence of rna-ligand interactions
JP2007535894A (ja) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
EP1635693A2 (de) * 2003-05-23 2006-03-22 Board Of Regents, The University Of Texas System Screening mit hohem durchsatz von aptamer-bibliotheken für die spezifische bindung an proteine auf viren und anderen erregern
CA2526690C (en) * 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
WO2004113495A2 (en) 2003-05-23 2004-12-29 The President And Fellows Of Harvard College Rna-based transcriptional regulators
DE10325152B4 (de) * 2003-05-30 2011-07-21 Kage, Andreas, Dr., 12207 Verfahren zur quantitativen Bestimmung einer unbekannten Menge einer Zielmolekülspezies
EP2267006A1 (de) 2003-05-30 2010-12-29 Intercell AG Enterokokken-Antigene
US20050250094A1 (en) * 2003-05-30 2005-11-10 Nanosphere, Inc. Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
EP1493810A1 (de) 2003-06-30 2005-01-05 Gentium S.p.A. Auf DNA-basierte Aptamere für Cathepsin G
EP1649018A2 (de) 2003-07-10 2006-04-26 Michigan State University Auf sp1 und sp3 abzielende krebstherapien und therapeutika
US20050118611A1 (en) * 2003-07-24 2005-06-02 Board Of Regents, The University Of Texas System Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
EP2216415B2 (de) 2003-08-01 2017-01-04 Life Technologies Corporation Zusammensetzungen und Verfahren zur Aufreinigung kurzer RNA-Moleküle und anderer Nukleinsäuren
US20050043245A1 (en) * 2003-08-11 2005-02-24 Siler -Khodr Theresa M. Non-mammalian GnRH analogs and uses thereof in the immune system
AU2004266213A1 (en) 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
CN102813923B (zh) * 2003-08-27 2015-04-01 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
US20050064435A1 (en) * 2003-09-24 2005-03-24 Xing Su Programmable molecular barcodes
EP1663199B1 (de) * 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen
CA2540472A1 (en) * 2003-09-30 2005-04-07 The Hospital For Sick Children Method of in situ detection of proteins using aptamers
US7803624B2 (en) 2003-09-30 2010-09-28 Cytyc Corporation Automated cytological sample classification
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US7223611B2 (en) * 2003-10-07 2007-05-29 Hewlett-Packard Development Company, L.P. Fabrication of nanowires
US7132298B2 (en) * 2003-10-07 2006-11-07 Hewlett-Packard Development Company, L.P. Fabrication of nano-object array
CN1894407A (zh) * 2003-11-10 2007-01-10 诺松制药股份公司 特异性结合生物活性生长素释放肽的核酸
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
WO2005051174A2 (en) * 2003-11-21 2005-06-09 The Trustees Of Columbia University In The City Of New York Nucleic acid aptamer-based compositions and methods
GB0328448D0 (en) * 2003-12-09 2004-01-14 Univ Leeds Agents for the regulation of transcription via zinc finger proteins
US20050123932A1 (en) * 2003-12-09 2005-06-09 Mekbib Astatke Nucleic acid-chelating agent conjugates
JP2007525661A (ja) * 2003-12-12 2007-09-06 セントルイス ユニバーシティー 大分子その他の分析物の検出用生物センサー
US7361410B2 (en) * 2003-12-29 2008-04-22 Intel Corporation External modification of composite organic inorganic nanoclusters comprising raman active organic compound
US20080076119A9 (en) * 2003-12-29 2008-03-27 Lei Sun Composite organic inorganic nanoclusters
US20050191665A1 (en) * 2003-12-29 2005-09-01 Xing Su Composite organic-inorganic nanoclusters
US20050147963A1 (en) * 2003-12-29 2005-07-07 Intel Corporation Composite organic-inorganic nanoparticles and methods for use thereof
WO2005079363A2 (en) 2004-02-12 2005-09-01 Archemix Corporation Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8389710B2 (en) 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
US8318920B2 (en) * 2004-02-27 2012-11-27 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
US7910297B2 (en) * 2004-02-27 2011-03-22 Operational Technologies Corporation Therapeutic nucleic acid-3' -conjugates
JP2007527246A (ja) * 2004-03-05 2007-09-27 アーケミックス コーポレイション ヒトｉｌ−１２サイトカインファミリーに対するアプタマーおよび自己免疫疾患の治療剤としてのそれらの使用
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2005092308A2 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7407738B2 (en) * 2004-04-02 2008-08-05 Pavel Kornilovich Fabrication and use of superlattice
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US20050239134A1 (en) * 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
WO2005106042A2 (en) 2004-04-22 2005-11-10 Regado Biosciences, Inc. Improved modulators of coagulation factors
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US7247531B2 (en) 2004-04-30 2007-07-24 Hewlett-Packard Development Company, L.P. Field-effect-transistor multiplexing/demultiplexing architectures and methods of forming the same
DE102004021707A1 (de) * 2004-04-30 2005-11-24 Cytotools Gmbh Verfahren zur Isolierung von spezifischen Molekülen, die hochselektiv an ausgewählte Zielmoleküle binden
US7683435B2 (en) 2004-04-30 2010-03-23 Hewlett-Packard Development Company, L.P. Misalignment-tolerant multiplexing/demultiplexing architectures
US20060024814A1 (en) * 2004-07-29 2006-02-02 Peters Kevin F Aptamer-functionalized electrochemical sensors and methods of fabricating and using the same
EP1781310B1 (de) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Artikel von peptidnanostrukturen und herstellungsverfahren dafür
US20070048797A1 (en) * 2004-08-11 2007-03-01 Xing Su Composite organic inorganic nanoclusters as carriers and identifiers of tester molecules
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US20060040258A1 (en) * 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
US20090104119A1 (en) * 2004-08-25 2009-04-23 Majoros Istvan J Dendrimer Based Compositions And Methods Of Using The Same
US20060046311A1 (en) * 2004-08-26 2006-03-02 Intel Corporation Biomolecule analysis using Raman surface scanning
US7776547B2 (en) * 2004-08-26 2010-08-17 Intel Corporation Cellular analysis using Raman surface scanning
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
JP2008512098A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006027780A2 (en) 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
JP5144267B2 (ja) * 2004-10-28 2013-02-13 アイデックス ラボラトリーズ，インコーポレイティド 医薬活性化合物を制御して搬送するための組成物
EP1807107B1 (de) 2004-11-02 2011-09-07 Archemix Corp. Stabiliserte aptamere für einen aus plättchen gewonnenen wachstumfaktor und ihre verwendung als krebstherapiemittel
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
BRPI0519468A2 (pt) 2004-12-27 2009-01-27 Silence Therapeutics Ag complexos de lipÍdeos revestido e seu uso
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
AU2005323463B2 (en) 2004-12-27 2009-11-19 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US20060147941A1 (en) * 2004-12-30 2006-07-06 Intel Corporation Methods and apparatus for SERS assay of biological analytes
US9505846B2 (en) * 2005-01-28 2016-11-29 Life Technologies Corporation Multi-component inhibitors of nucleic acid polymerases
US7375012B2 (en) * 2005-02-28 2008-05-20 Pavel Kornilovich Method of forming multilayer film
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
AU2006220621A1 (en) * 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
US20060205090A1 (en) * 2005-03-14 2006-09-14 Newton Michael W Water-soluble conjugates for electrochemical detection
CA2602602A1 (en) * 2005-03-24 2006-09-28 Syracuse University Elucidation of high affinity, high specificity oligonucleotides and derivatized oligonucleotide sequences for target recognition
JPWO2006103772A1 (ja) * 2005-03-30 2008-09-04 Ｎｅｃソフト株式会社 グルタチオン−ｓ−トランスフェラーゼ・タンパク質に対する高親和性ｒｎａアプタマー分子
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
DE102005022057B3 (de) * 2005-05-09 2007-02-08 Analyticon Biotechnologies Ag Verfahren zur Herstellung von Liganden, Liganden und Test-Kit
WO2006125094A2 (en) * 2005-05-18 2006-11-23 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate aptamers for rnases
US8956857B2 (en) 2005-06-06 2015-02-17 Mediomics, Llc Three-component biosensors for detecting macromolecules and other analytes
US7795009B2 (en) * 2005-06-15 2010-09-14 Saint Louis University Three-component biosensors for detecting macromolecules and other analytes
EP1907410B1 (de) 2005-06-10 2012-07-04 Saint Louis University Verfahren zur selektion von aptameren
US7811809B2 (en) * 2005-06-15 2010-10-12 Saint Louis University Molecular biosensors for use in competition assays
WO2007005426A2 (en) * 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
AU2006265896B2 (en) 2005-06-30 2012-05-31 Archemix Corp. Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
KR20080036595A (ko) 2005-07-05 2008-04-28 가부시키가이샤 리보믹 면역글로불린 ｇ에 결합하는 핵산과 그 이용법
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
US20100254901A1 (en) * 2005-07-28 2010-10-07 Smith Cassandra L Compositions comprising nucleic acid aptamers
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168402B2 (en) * 2005-11-03 2012-05-01 Lohocla Research Corporation Diagnostic tests of substance use disorders
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
US20090246189A1 (en) 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US8017159B2 (en) * 2005-11-16 2011-09-13 Idexx Laboratories, Inc. Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same
US8188260B2 (en) * 2005-12-06 2012-05-29 The University Of Tokyo Versatile acylation catalytic RNAs and uses thereof
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
US20070155022A1 (en) * 2005-12-30 2007-07-05 Mineo Yamakawa Degenerate binding detection and protein identification using Raman spectroscopy nanoparticle labels
CA2646833C (en) 2005-12-30 2019-07-30 Evonik Roehm Gmbh Peptides useful as cell-penetrating peptides
US20070239483A1 (en) * 2006-01-09 2007-10-11 Biophysical Corporation Methods for individualized health assessment service
AU2006335290A1 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
WO2007084886A2 (en) 2006-01-17 2007-07-26 Somalogic, Incorporated Multiplexed analyses of test samples
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
US7922000B2 (en) * 2006-02-15 2011-04-12 Miraial Co., Ltd. Thin plate container with a stack of removable loading trays
US8460878B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for detecting cells and cellular components in small defined volumes
JP5406534B2 (ja) 2006-03-08 2014-02-05 アーケミックス エルエルシー 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤
WO2008076139A1 (en) * 2006-03-10 2008-06-26 Tethys Bioscience, Inc. Multiplex protein fractionation
US20070231855A1 (en) * 2006-03-28 2007-10-04 Fujitsu Limited Functional molecule and manufacturing method therefor
JP4984990B2 (ja) * 2006-03-28 2012-07-25 富士通株式会社 機能性分子の製造方法
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
JP2009534342A (ja) 2006-04-20 2009-09-24 サイレンス・セラピューティクス・アーゲー 血管内皮に特異的に送達するためのリポプレックス処方剤
US20080020475A1 (en) * 2006-05-05 2008-01-24 Rules-Based Medicine, Inc Methods and kits for the diagnosis of hypothyroidism
US20080014589A1 (en) 2006-05-11 2008-01-17 Link Darren R Microfluidic devices and methods of use thereof
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
DE202006007590U1 (de) 2006-05-12 2006-12-14 Osaka University Verwendung einer Zusammensetzung, die Sema7A- und VLA-1-Interaktion inhibiert, zum Behandeln von Cytokin-vermittelten Erkrankungen
EP2019691B1 (de) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymere für funktionelle partikel
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20070292397A1 (en) * 2006-06-19 2007-12-20 Mcnulty Amy K Method for the detection and neutralization of bacteria
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
EP2049151A4 (de) * 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
WO2008011157A2 (en) 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US7645582B2 (en) * 2006-07-21 2010-01-12 Hitachi Chemical Co., Ltd. Aptamers that bind to listeria surface proteins
RU2553561C2 (ru) 2006-07-21 2015-06-20 Сайленс Терапьютикс Аг Средства ингибирования экспрессии протеинкиназы 3
WO2008011608A2 (en) * 2006-07-21 2008-01-24 Hitachi Chemical Co., Ltd. Nucleic acid ligands capable of binding to internalin b or internalin a
US20080031903A1 (en) * 2006-07-27 2008-02-07 Andrea Gambotto Method of treating ocular infections
CA2658105C (en) * 2006-08-01 2016-07-05 Gen-Probe Incorporated Methods of nonspecific target capture of nucleic acids
EP2048246B1 (de) 2006-08-03 2011-09-14 NEC Soft, Ltd. Verfahren zur gewinnung eines oligonukleotids
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US20080070802A1 (en) * 2006-08-23 2008-03-20 Moerschell Richard P Directed heterobifunctional linkers
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
JP4841396B2 (ja) 2006-10-18 2011-12-21 Ｎｅｃソフト株式会社 塩基配列の同定装置、核酸分子の二次構造取得装置、塩基配列の同定方法、核酸分子の二次構造取得方法、プログラム及び記録媒体
EP1913955A1 (de) 2006-10-19 2008-04-23 Gerhard, Markus Neue Methode zur Behandlung von Infektionen durch H. pylori
US7598040B2 (en) * 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
EP3095455A1 (de) 2006-12-19 2016-11-23 Genentech, Inc. Vegf-spezifische antagonisten für adjuvans- und neoadjuvanstherapie und zur therapie von tumoren im frühstadium
WO2008089059A1 (en) * 2007-01-12 2008-07-24 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of galactosemia
US7964356B2 (en) * 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) * 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US20110136099A1 (en) * 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8586303B1 (en) 2007-01-22 2013-11-19 Steven Albert Benner In vitro selection with expanded genetic alphabets
US9725713B1 (en) 2007-01-22 2017-08-08 Steven A Benner In vitro selection with expanded genetic alphabets
EP2111553B1 (de) 2007-01-24 2018-09-19 Carnegie Mellon University Optische biosensoren
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US20080255766A1 (en) * 2007-02-16 2008-10-16 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
WO2008109797A1 (en) * 2007-03-08 2008-09-12 Rules-Based Medicine, Inc. Methods for rapid disease screening
DE102007011702A1 (de) 2007-03-08 2008-09-11 Rheinische Friedrich-Wilhelms Universität Aptamer-basierte Reagenzien
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
DK2132339T3 (da) * 2007-04-04 2011-06-27 Chimera Biotec Gmbh Fremgangsmåde til detektering af en analyt i en biologisk matrix
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US20080248958A1 (en) * 2007-04-05 2008-10-09 Hollenbach Andrew D System for pulling out regulatory elements in vitro
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20090088376A1 (en) * 2007-04-19 2009-04-02 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
CA2684998A1 (en) 2007-04-30 2009-01-29 Nanogen, Inc. Multianalyte assay
EP2497779A1 (de) 2007-05-02 2012-09-12 Intercell AG Klebsiella-Antigene
CA2690271A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
NO2933340T3 (de) 2007-07-17 2018-02-03
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
FR2920024B1 (fr) 2007-08-14 2012-12-14 Lfb Biotechnologies Procede de purification ou de detection d'une proteine cible
WO2009026540A1 (en) 2007-08-22 2009-02-26 Colorado School Of Mines Lanthanide nanoparticle conjugates and uses thereof
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102007041476B4 (de) 2007-08-31 2017-03-30 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
WO2009032901A1 (en) * 2007-09-04 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biosensors and related methods
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
US20090068669A1 (en) * 2007-09-12 2009-03-12 Elias Georges Slc9a3r1 directed diagnostics for neoplastic disease
US20100291032A1 (en) * 2007-09-14 2010-11-18 Trana Discovery Compositions and methods for the identification of inhibitors of retroviral infection
EP2195432B1 (de) * 2007-09-24 2015-12-09 Performance Plants, Inc. Pflanzen mit erhöhter biomasse
US20100204303A1 (en) * 2007-09-25 2010-08-12 Idexx Laboratories, Inc. Pharmaceutical Compositions for Administering Oligonucleotides
SG10202100638XA (en) 2007-10-02 2021-02-25 Theranos Ip Co Llc Modular Point-Of-Care Devices And Uses Thereof
WO2009073063A2 (en) * 2007-10-05 2009-06-11 The Regents Of The University Of California High-stringency screening of target-binding partners using a microfludic device
EP2045326A1 (de) * 2007-10-05 2009-04-08 Bayer CropScience AG Verfahren zum Identifizieren des Interaktionspartners eines Wirkstoffes
EP2205271B1 (de) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Zusammensetzungen und verfahren für therapien auf ribonukleasebasis
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
US20090163437A1 (en) * 2007-10-16 2009-06-25 Regado Biosciences, Inc. Steady-state subcutaneous administration of aptamers
US9315804B2 (en) 2007-10-22 2016-04-19 Caris Life Sciences Switzerland Holdings, GmbH Method of selecting aptamers
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
US20100233678A1 (en) * 2007-11-13 2010-09-16 Beadling Leslie C Tunable affinity ligands for the separation and detection of target substances
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
WO2009076323A2 (en) 2007-12-06 2009-06-18 Genalyte Inc. Monitoring enzymatic process
US8865401B2 (en) 2007-12-14 2014-10-21 The Johns Hopkins University Purification and concentration of proteins and DNA from a complex sample using isotachophoresis and a device to perform the purification
WO2009078939A1 (en) * 2007-12-17 2009-06-25 Brown University Methods for identifying nucleotide ligands
EP2240778B1 (de) 2008-01-07 2014-07-23 Luminex Corporation Isolierung und identifizierung von zellen aus einer komplexen probenmatrix
EP3181588A1 (de) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Cadherin-11 antagonisten und verfahren zur behandlung entzündlichen gelenkerkrankungen
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
WO2009100131A2 (en) 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates
AU2009258033A1 (en) * 2008-03-12 2009-12-17 Syracuse University Direct selection of structurally defined aptamers
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US9115352B2 (en) 2008-03-31 2015-08-25 Sloning Biotechnology Gmbh Method for the preparation of a nucleic acid library
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
AU2009233708B2 (en) 2008-04-09 2015-06-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2009242486B2 (en) 2008-05-02 2013-10-10 Cellscript, Inc. RNA polyphosphatase compositions, kits, and uses thereof
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
US20120003749A1 (en) * 2008-05-21 2012-01-05 Nec Soft, Ltd. Nucleic acid molecule capable of binding to 2,4,6-trinitrophenyl skeleton, method for detecting compound having 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, and use of the nucleic acid molecule
MX350760B (es) 2008-06-06 2017-09-18 Danisco Us Inc Alfa-amilasas variantes de bacillus subtilis y metodos de uso de las mismas.
US8722638B2 (en) * 2008-06-20 2014-05-13 Children's Medical Center Corporation Methods for the modulation of angiogenesis
AU2009273052B2 (en) * 2008-07-14 2015-09-17 The University Of Tokyo Aptamer against IL-17 and use thereof
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
EP2338051B1 (de) 2008-07-17 2013-11-20 IKFE Institut für klinische Forschung und Entwicklung GmbH Biomarker für kardiodiabetes
AU2009270682B2 (en) 2008-07-17 2016-04-21 Ikfe Lnstitut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for insulin resistance and beta-cell dysfunction
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
ES2665245T3 (es) * 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
US20100068729A1 (en) * 2008-09-12 2010-03-18 Rules-Based Medicine, Inc. Method and kits for the diagnosis of diabetes
ES2543222T3 (es) 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
WO2010036795A2 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010039985A1 (en) 2008-10-01 2010-04-08 Quintessence Biosciences, Inc. Therapeutic Ribonucleases
WO2010042823A1 (en) 2008-10-09 2010-04-15 Northeastern Universtiy Multifunctional self-assembling polymeric nanosystems
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
AU2009308293B2 (en) 2008-10-22 2015-02-05 Genentech, Inc. Modulation of axon degeneration
EP3572796B8 (de) 2008-10-27 2023-01-18 Genalyte, Inc. Biosensoren basierend auf optischer sondierung und abtastung
MX2011004501A (es) 2008-10-29 2011-11-18 Bg Medicine Inc Inmunoensayo de galectina-3.
ES2732504T3 (es) 2008-10-29 2019-11-22 Circular Commitment Company Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
CN102317779A (zh) 2008-11-21 2012-01-11 圣路易大学 检测目标物多个表位的生物感应器
CA2782776A1 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
CA2688174C (en) 2008-12-19 2018-08-07 F. Hoffmann-La Roche Ag Dry composition of reaction compounds with stabilized polymerase
WO2010076655A1 (en) 2008-12-30 2010-07-08 Ikfe Gmbh Biomarkers for adipose tissue activity
WO2010079428A2 (en) 2009-01-07 2010-07-15 Ikfe Gmbh Biomarkers for appetite regulation
CA2761389A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
ES2945533T3 (es) 2009-02-13 2023-07-04 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
CA2752854A1 (en) 2009-02-18 2010-08-26 Carnegie Mellon University Quenched dendrimeric dyes for bright detection
FR2942232B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre
ES2684493T3 (es) 2009-03-11 2018-10-03 Promedior Inc. Un polipéptido SAP para uso en el tratamiento de trastornos autoinmunitarios y enfermedad del injerto contra el huésped
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
EP2411148B1 (de) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation von mikrofluidiktröpfchen
JP5561755B2 (ja) 2009-04-01 2014-07-30 Ｎｅｃソリューションイノベータ株式会社 Ｓｅｌｅｘ法用のプライマーの設計方法、プライマーの製造方法、アプタマーの製造方法、プライマーの設計装置、プライマー設計用コンピュータプログラムおよび記録媒体
DE202010018378U1 (de) 2009-04-10 2016-04-07 Tufts Medical Center, Inc. PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1)
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9125861B2 (en) 2009-05-04 2015-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) PAR2 agonists for use in the treatment or prevention of influenza virus type A infections
CA2760774A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
US20100291706A1 (en) 2009-05-15 2010-11-18 Millipore Corporation Dye conjugates and methods of use
KR20120016297A (ko) 2009-06-01 2012-02-23 코넬 유니버시티 미소구를 이용한 통합 광학유체 시스템
JP2012528597A (ja) 2009-06-03 2012-11-15 レガド・バイオサイエンシズ・インク 血小板グリコプロテインｖｉの核酸調節因子
US9187757B2 (en) 2009-06-05 2015-11-17 University Of Florida Research Foundation, Inc. Isolation and targeted suppression of lignin biosynthetic genes
EP2440284B1 (de) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nervenmanschette mit tasche für einen bleifreien stimulator
TWI532842B (zh) 2009-06-11 2016-05-11 力博美科股份有限公司 針對凝乳酶之適體及其用途
EP2997974B1 (de) 2009-06-19 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung neurodegenerativer erkrankungen
JP5875514B2 (ja) 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
WO2010149765A1 (en) 2009-06-26 2010-12-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non human animal models for increased retinal vascular permeability
AU2013203588C1 (en) * 2009-07-09 2016-06-30 Somalogic Operating Co., Inc. Method for generating aptamers with improved off-rates
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
GB0913258D0 (en) 2009-07-29 2009-09-02 Dynex Technologies Inc Reagent dispenser
US9523701B2 (en) 2009-07-29 2016-12-20 Dynex Technologies, Inc. Sample plate systems and methods
FR2948665B1 (fr) 2009-07-31 2011-09-23 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla actives
FR2948664B1 (fr) 2009-07-31 2013-11-01 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla
US9250234B2 (en) 2011-01-19 2016-02-02 Ohmx Corporation Enzyme triggered redox altering chemical elimination (E-TRACE) immunoassay
EP2642291B1 (de) 2009-08-07 2015-10-07 Ohmx Corporation Enzym-gesteuerter Redox-ändernder chemischer Eliminierungs- (E-trace)- Immunassay
GB0914318D0 (en) 2009-08-14 2009-09-30 Medical Res Council Method
US8898069B2 (en) * 2009-08-28 2014-11-25 The Invention Science Fund I, Llc Devices and methods for detecting an analyte in salivary fluid
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
WO2011023824A2 (en) 2009-08-31 2011-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells
EP2478360B1 (de) 2009-09-14 2018-06-27 Banyan Biomarkers, Inc. Autoantikörpermarker zur diagnose von traumatischen läsionen am gehirn
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
AU2010318637A1 (en) 2009-10-13 2012-05-31 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
US20120328609A1 (en) 2009-10-22 2012-12-27 Genentech, Inc. Modulation of Axon Degeneration
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
WO2011054916A1 (en) 2009-11-06 2011-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of atherosclerosis
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
AU2010321885B2 (en) 2009-11-20 2015-12-24 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
ES2638370T3 (es) 2009-11-23 2017-10-20 Inserm - Institut National De La Santé Et De La Recherche Médicale Inhibidores del complejo PP1/GADD34 para el tratamiento de una afección que requiera una actividad inmunosupresora
DE102009056944A1 (de) 2009-12-07 2011-06-09 Christian-Albrechts-Universität Zu Kiel RNA-Aptamere, die den löslichen Interleukin-6-Rezeptor spezifisch binden
DE102009056945A1 (de) 2009-12-07 2011-06-16 Christian-Albrechts-Universität Zu Kiel DNA-Aptamere, die den löslichen Interleukin-6-Rezeptor spezifisch binden
CN105126248B (zh) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
EP2523661B1 (de) 2010-01-15 2017-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitoren zur behandlung von autismus
US8969061B2 (en) 2010-01-20 2015-03-03 New England Biolabs, Inc. Compositions, methods and related uses for cleaving modified DNA
US20110201076A1 (en) 2010-01-22 2011-08-18 Colorado School Of Mines Harvesting micro algae
US20130149314A1 (en) 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2011099576A1 (ja) 2010-02-12 2011-08-18 国立大学法人 東京大学 Ｆｇｆ２に対するアプタマー及びその使用
EP2534267B1 (de) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digitale analyse von analyten
CA2787483C (en) 2010-02-12 2018-03-06 Saint Louis University Molecular biosensors capable of signal amplification
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
AU2011218125A1 (en) 2010-02-18 2012-07-19 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9678068B2 (en) 2010-03-01 2017-06-13 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
CN103026232B (zh) 2010-03-01 2015-02-04 匡特里克斯公司 扩大用于检测分子或颗粒的测定法中的动态范围的方法和系统
AU2011223527B2 (en) 2010-03-03 2014-11-13 Somalogic Operating Co., Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
WO2011113118A1 (en) 2010-03-19 2011-09-22 Katholieke Universiteit Leuven Drug tolerance/persistence of fungal biofilms
JP5027956B2 (ja) 2010-03-24 2012-09-19 株式会社リボミック Ｎｇｆに対するアプタマー及びその使用
JP2013524220A (ja) 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ
NZ602845A (en) 2010-04-08 2015-05-29 Inst Nat Sante Rech Med Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
CN102858990B (zh) 2010-04-12 2016-08-03 私募蛋白质体公司 针对β-NGF的适体及其在治疗β-NGF介导的疾病和失调中的用途
EP2577309B1 (de) 2010-05-25 2016-11-23 Carnegie Mellon University Gezielte sonden für zellphysiologie
US20130116129A1 (en) * 2010-07-01 2013-05-09 National Institute Of Advanced Industrial Science And Technology Method for detecting target molecules
AU2011272235B2 (en) * 2010-07-02 2014-09-11 Kanagawa Prefectural Hospital Organization Prediction device, prediction method, program, and recording medium
NO2593128T3 (de) 2010-07-15 2018-06-09
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
JP5903718B2 (ja) 2010-08-09 2016-04-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｉｖ−１感染の処置のための方法及び医薬的組成物
US20120077191A1 (en) 2010-08-11 2012-03-29 Celula, Inc. Genotyping dna
WO2012021913A1 (en) 2010-08-18 2012-02-23 University Of Graz Methods for increasing resistance of plants to drought, salt and pathogens
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US20130183718A1 (en) 2010-09-21 2013-07-18 RibpxX GmbH Method for Synthesizing RNA using DNA Template
CA2809282C (en) 2010-09-27 2017-09-12 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
SG189856A1 (en) 2010-10-14 2013-06-28 Regado Biosciences Inc Nucleic acid modulators of clec-2
EP2628013B1 (de) 2010-10-14 2019-06-12 The Johns Hopkins University Biomarker für gehirnverletzungen
WO2012061778A2 (en) 2010-11-05 2012-05-10 Genalyte, Inc. Optical analyte detection systems and methods of use
US9072766B2 (en) 2010-11-18 2015-07-07 Beth Israel Deaconess Medical Center, Inc. Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
WO2012095303A1 (en) 2011-01-10 2012-07-19 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
CN106290160A (zh) 2011-01-21 2017-01-04 提拉诺斯公司 样品使用最大化的系统和方法
EP2673301A2 (de) 2011-02-09 2013-12-18 Cancer Research Technology Limited Frmd4a-antagonisten und ihre verwendung
EP3412778A1 (de) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP2696898A4 (de) 2011-04-07 2014-10-01 Univ Emory Zusammensetzungen mit saccharidbindenden teilen und verfahren für eine gezielte therapie
ES2741282T3 (es) 2011-05-05 2020-02-10 Matinas Biopharma Nanotechnologies Inc Composiciones de cocleato y métodos de elaboración y uso de las mismas
WO2012152711A1 (en) 2011-05-06 2012-11-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for identifying aptamers
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2707389B1 (de) 2011-05-12 2019-10-30 The Johns Hopkins University Testreagenzien für eine neurogranin-diagnosekit
WO2012156476A2 (en) 2011-05-16 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening substances capable of modulating the replication of an influenza virus
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
GB201110371D0 (en) 2011-06-17 2011-08-03 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US20140243391A1 (en) 2011-07-22 2014-08-28 Centre National De La Recherche Scientifique Phospholipid-detergent conjugates and uses thereof
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
AU2012295913A1 (en) 2011-08-12 2014-03-13 Tagcyx Biotechnologies Production method for nucleic acid aptamer
GB201114662D0 (en) 2011-08-24 2011-10-12 Altermune Technologies Llc Chemically programmable immunity
EP2753697A1 (de) 2011-09-05 2014-07-16 ETH Zürich Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
WO2013034687A1 (en) 2011-09-09 2013-03-14 Universität Bern Verwaltungsdirektion Avibacterium paragallinarum rtx toxin
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
WO2013040577A1 (en) 2011-09-16 2013-03-21 The Research Foundation Of State University Of New York Aptamers resistant to nucleocapsid degradation
CA2846630A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
JP6118724B2 (ja) 2011-09-28 2017-04-19 株式会社リボミック Ｎｇｆに対するアプタマー及びその用途
BR112014007501A2 (pt) 2011-09-30 2017-04-04 Mallinckrodt Llc conjunto remoto de nanopartículas direcionadas usando ligantes de oligonucleotídeos complementares
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
JP6203183B2 (ja) 2011-10-17 2017-09-27 オームクス コーポレイション 酵素誘発レドックス変化化学的脱離（ｅ−ｔｒａｃｅ）イムノアッセイを使用する、ヘモグロビンａ１ｃのパーセンテージの単回直接検出
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
WO2013065016A1 (en) 2011-11-02 2013-05-10 University Of Cape Town A method of detecting and/or quantifying an analyte in a biological sample
EP2773650A1 (de) 2011-11-04 2014-09-10 Ohmx Corporation Neue chemische vorgänge in biosensoren
CN105462984B (zh) 2011-11-18 2019-05-21 塔古西库斯生物株式会社 与靶蛋白质结合的核酸片段
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
WO2013079701A2 (en) 2011-11-30 2013-06-06 University Of Bremen Expression of mirnas in placental tissue
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
WO2013106434A1 (en) 2012-01-09 2013-07-18 Ohmx Corporation Enzyme cascade methods for e-trace assay signal amplification
KR102138106B1 (ko) 2012-01-31 2020-07-28 더유니버시티오브톨레도 피분석물을 검출 및 측정하기 위한 방법 및 장치
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
WO2013138251A1 (en) 2012-03-12 2013-09-19 The Board Of Trustes Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9133515B2 (en) 2012-05-16 2015-09-15 Silence Therapeutics Gmbh Use of VEGFR1 as a biomarker
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
SG10201701361WA (en) 2012-06-07 2017-04-27 Somalogic Inc Aptamer-based multiplexed assays
US8790400B2 (en) 2012-06-13 2014-07-29 Elwha Llc Breast implant with covering and analyte sensors responsive to external power source
US8795359B2 (en) 2012-06-13 2014-08-05 Elwha Llc Breast implant with regionalized analyte sensors and internal power source
US9144489B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with covering, analyte sensors and internal power source
US9144488B2 (en) 2012-06-13 2015-09-29 Elwha Llc Breast implant with analyte sensors responsive to external power source
US8808373B2 (en) 2012-06-13 2014-08-19 Elwha Llc Breast implant with regionalized analyte sensors responsive to external power source
US9211185B2 (en) 2012-06-13 2015-12-15 Elwha Llc Breast implant with analyte sensors and internal power source
US9803197B2 (en) 2012-06-25 2017-10-31 Emory University Particle-nucleic acid conjugates and therapeutic uses related thereto
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP6199387B2 (ja) 2012-07-27 2017-09-20 オームクス コーポレイション 構成要素の均一反応後の単分子層の電子測定
US9416390B2 (en) 2012-07-27 2016-08-16 Ohmx Corporation Electric measurement of monolayers following pro-cleave detection of presence and activity of enzymes and other target analytes
BR112015002287A2 (pt) 2012-07-31 2017-07-04 Joaquin Lopez processo para obtenção e detecção de um marcador de objetos a serem identificados, o marcador, método para autenticação e método para verificação
US9840712B2 (en) * 2012-08-02 2017-12-12 Deakin University CD133 aptamers for detection of cancer stem cells
CA2880833A1 (en) 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
AU2013340414B2 (en) 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
EP2912432B1 (de) 2012-10-24 2018-07-04 Genmark Diagnostics Inc. Integrierte multiplex-zielanalyse
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CA2895847C (en) 2012-12-19 2019-01-08 Caris Science, Inc. Compositions and methods for aptamer screening
FR3000105B1 (fr) 2012-12-24 2015-05-15 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la tyrosinase
WO2014121256A1 (en) 2013-02-04 2014-08-07 The Cleveland Clinic Foundation Aptamers for tumor initiating cells
WO2014126213A1 (ja) 2013-02-15 2014-08-21 Ｎｅｃソリューションイノベータ株式会社 類似判断の候補配列情報の選択装置、選択方法、およびそれらの用途
WO2016028749A1 (en) 2014-08-20 2016-02-25 Memorial Sloan Kettering Cancer Center Raman-triggered ablation/resection systems and methods
EP2774930A1 (de) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocenverbindungen und markierte Moleküle damit für In-vivo-Bildgebung
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
US9052314B2 (en) 2013-03-14 2015-06-09 Silver Lake Research Corporation Biomarkers for detecting the presence of bacteria
JP6683598B2 (ja) 2013-03-15 2020-04-22 マックスサイト インコーポレーティッド 安定なトランスフェクトされた細胞を生成するための方法および組成物
EP2972386B1 (de) 2013-03-15 2018-01-10 Somalogic, Inc. Biomarker für nichtalkoholische fettlebererkrankung und nichtalkoholische steatohepatitis und verwendungen davon
WO2014143637A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
WO2014148638A1 (ja) 2013-03-22 2014-09-25 国立大学法人東京大学 Ｉｌ－１７に対するアプタマー及びその使用
CN105264374A (zh) 2013-03-27 2016-01-20 赛拉诺斯股份有限公司 用于样品分析的方法、装置和系统
CA2913334A1 (en) 2013-05-23 2014-11-27 Iphenotype Llc Method and system for maintaining or improving wellness
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
WO2014197965A1 (en) 2013-06-12 2014-12-18 The Governing Council Of The University Of Toronto Catalytic nucleic acid and gold nanoparticles for detection of biomolecules
JP6600302B2 (ja) 2013-06-12 2019-10-30 ザ ジェネラル ホスピタル コーポレイション 標的分子のマルチプレックス検出のための方法、キット、およびシステム、ならびにそれらの使用
CN105308073B (zh) 2013-06-14 2019-08-13 加利福尼亚太平洋生物科学股份有限公司 双生物素化标签
WO2014210219A1 (en) 2013-06-25 2014-12-31 Two Pore Guys, Inc. Multiplexed biomarker quantitation by nanopore analysis of biomarker-polymer complexes
SG11201510369WA (en) 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
SG10201708882TA (en) 2013-07-12 2017-12-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
EP3022322A4 (de) 2013-07-17 2017-05-17 The Johns Hopkins University Multiprotein-biomarkertest für den nachweis von hirnläsionen und ergebnis
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
GB201314485D0 (en) 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
EP2837939A1 (de) 2013-08-13 2015-02-18 Technische Universität München Verfahren zum Nachweis von H.pylori-Infektionen
BR102013021701A2 (pt) 2013-08-26 2015-07-28 Univ São Paulo Usp Polinucleotídeos quimicamente modificados e processo de produção de polinucleotídeos quimicamente modificados
BR112016004153A2 (pt) 2013-08-28 2019-09-17 Caris Life Sciences Switzerland Holdings Gmbh "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
GB201315743D0 (en) 2013-09-04 2013-10-16 Maersk Olie & Gas Provision and uses of wettability modifiers
US11545241B1 (en) 2013-09-07 2023-01-03 Labrador Diagnostics Llc Systems and methods for analyte testing and data management
CA3221709A1 (en) 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
EP3046564A1 (de) 2013-09-16 2016-07-27 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von epilepsie
US10124001B2 (en) 2013-09-18 2018-11-13 University Of Canberra Stem cell modulation II
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
EP3718558A1 (de) 2013-10-08 2020-10-07 Promedior, Inc. Verfahren zur behandlung fibrotischer karzinome
WO2015062743A1 (en) 2013-11-04 2015-05-07 Noxxon Pharma Ag Means and methods for the treatment of nephropathy
GB201320061D0 (en) 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
US20160274095A1 (en) 2013-11-13 2016-09-22 Inserm (Institut National De La Sante Et De La Recherche Medicale Kits-of-Parts Comprising Nucleic Acids Able to Form a Kissing Complex and Their uses Thereof
AR093574A1 (es) 2013-11-21 2015-06-10 Consejo Nac De Investig Cientificas Y Tecn (Conicet) Aptameros contra la proteina basica de mielina como agentes neuroprotectores
EP3071588A4 (de) 2013-11-21 2017-08-02 Somalogic, Inc. Cytidin-5-carboxamid-modifizierte nukleotidzusammensetzungen und zugehörige verfahren
DE102013112915A1 (de) 2013-11-22 2015-05-28 Universitätsklinikum Hamburg-Eppendorf (UKE) DNA-Aptamere, die E- und P-Selektine spezifisch binden
AU2014359716A1 (en) 2013-12-05 2016-06-09 Silence Therapeutics Gmbh Means for lung specific delivery
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
SG11201604875PA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
EP3090063B1 (de) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Verfahren zur detektion von latentem retrovirus
EP3092256B1 (de) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Verbindungen und zusammensetzungen für die immuntherapie
JP6636436B2 (ja) 2014-02-05 2020-01-29 ディーキン・ユニバーシティー アプタマー構築体
WO2015120382A1 (en) 2014-02-07 2015-08-13 The Johns Hopkins University Predicting response to epigenetic drug therapy
CN116334088A (zh) 2014-02-18 2023-06-27 私募蛋白质体运营有限公司 用于检测微生物的组合物和方法
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
CA2943093A1 (en) 2014-03-17 2015-09-24 Glaxosmithkline Intellectual Property Development Limited Aptamers for topical delivery
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
HUE048529T2 (hu) 2014-03-24 2020-07-28 Ribomic Inc FGF2-hez kötõdõ aptamer és alkalmazása
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA52909A (fr) 2014-04-18 2021-04-21 Acceleron Pharma Inc Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
WO2015164617A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Tuberculosis biomarkers in urine and uses thereof
WO2015164616A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
WO2015168302A1 (en) 2014-04-29 2015-11-05 Ohmx Corporation Bioelectronic binding assay using peak profiling
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
WO2016025539A1 (en) 2014-08-11 2016-02-18 Ohmx Corporation Enzyme triggered redox altering chemical elimination (-trace) assay with multiplexing capabilities
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
AU2015308721B2 (en) 2014-08-29 2021-04-01 Children's Medical Center Corporation Methods and compositions for the treatment of cancer
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3191843A1 (de) 2014-09-12 2017-07-19 Mediomics, LLC Molekulare biosensoren mit einem modularen design
US10222386B2 (en) 2014-09-19 2019-03-05 The Johns Hopkins University Biomarkers of congnitive dysfunction
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
EP3000483A1 (de) 2014-09-29 2016-03-30 Charité - Universitätsmedizin Berlin Mittel und Verfahren zur Diagnose und Behandlung von neurodegenerativen Erkrankungen
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
US11124822B2 (en) 2014-10-17 2021-09-21 Carnegie Mellon University Enhanced biomolecule detection assays based on tyramide signal amplification and gammaPNA probes
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
BR112017008628A2 (pt) 2014-11-06 2018-01-30 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
MX2017006521A (es) 2014-11-24 2017-08-09 Somalogic Inc Compuestos de acido nucleico para unirse al factor de diferenciacion de crecimiento 11.
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
SG11201705064XA (en) 2014-12-24 2017-07-28 Neximmune Inc Nanoparticle compositions and methods for immunotherapy
WO2016123058A1 (en) 2015-01-27 2016-08-04 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
RS61924B1 (sr) 2015-02-02 2021-06-30 Meiragtx Uk Ii Ltd Regulacija genske ekspresije putem aptamerom posredovane modulacije alternativnog splajsovanja
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10370669B2 (en) 2015-02-09 2019-08-06 Somalogic, Inc. Nucleic acid compounds for binding growth differentiation factor 8
EP3259594A4 (de) 2015-02-20 2018-12-26 The Johns Hopkins University Biomarker für myokardläsion
WO2016135300A1 (en) 2015-02-26 2016-09-01 Qiagen Gmbh Efficiency improving methods for gene library generation
US10620185B2 (en) 2015-02-27 2020-04-14 Aptascan, Inc. Molecular barcoded bi-stable switch
EP3262185B1 (de) 2015-02-27 2020-08-26 The University of Hong Kong Dna-anzeige und verfahren dafür
US9863930B2 (en) 2015-02-27 2018-01-09 Aptascan, Inc. Molecular barcoded bi-stable switch
AU2016229076B2 (en) 2015-03-09 2022-01-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
US10138486B2 (en) 2015-03-12 2018-11-27 The Regents Of The University Of Michigan Inhibitors of DEK protein and related methods
US9925122B2 (en) 2015-03-30 2018-03-27 Elwha Llc Systems and methods for controlling delivery of breast milk supplementation
US9968523B2 (en) 2015-03-30 2018-05-15 Elwha Llc Systems and devices for controlling delivery of breast milk supplementation
US10016341B2 (en) 2015-03-30 2018-07-10 Elwha Llc Systems and devices for controlling delivery of breast milk supplementation
US10290372B2 (en) 2015-03-30 2019-05-14 Elwha Llc Systems and devices for controlling delivery of breast milk supplementation
KR20170132234A (ko) * 2015-03-30 2017-12-01 닛산 가가쿠 고교 가부시키 가이샤 혈관 내피 증식 인자 수용체에 결합하는 핵산 앱타머
CN107666962B (zh) 2015-04-03 2021-03-09 雅培制药有限公司 用于样品分析的装置和方法
AU2016243036B2 (en) 2015-04-03 2022-02-17 Abbott Laboratories Devices and methods for sample analysis
AU2016244750B2 (en) 2015-04-06 2021-02-18 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN107980059B (zh) 2015-04-13 2022-11-11 美克斯细胞有限公司 用于修饰基因组dna的方法和组合物
WO2016182967A1 (en) 2015-05-08 2016-11-17 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
EP3302467A4 (de) 2015-05-31 2019-01-02 Curegenix Corporation Kombinationszusammensetzungen zur immuntherapie
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
JP2018518169A (ja) 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
EP4257134A3 (de) 2015-06-25 2024-01-24 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
WO2017004463A1 (en) 2015-07-01 2017-01-05 Abbott Laboratories Devices and methods for sample analysis
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
WO2017176265A1 (en) 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US10407484B2 (en) 2015-09-02 2019-09-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
DK3344805T3 (da) 2015-09-04 2022-03-07 Neoventures Biotechnology Inc Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3347720A1 (de) 2015-09-09 2018-07-18 Somalogic, Inc. Verfahren zur entwicklung personalisierter arzneimittelbehandlungspläne und gezielte arzneimittelentwicklung auf basis von proteomischen profilen
CN113912724A (zh) 2015-09-25 2022-01-11 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
EP3371311B1 (de) 2015-11-06 2021-07-21 Orionis Biosciences BV Bifunktionale chimäre proteine und verwendungen davon
SG10202004259PA (en) 2015-11-19 2020-06-29 Asclepix Therapeutics Llc Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
WO2017089593A1 (en) 2015-11-26 2017-06-01 Universite Paris Descartes Inhibitors for treating or preventing a pulmonary arterial hypertension in systemic sclerosis patients and method for diagnosing said disease
JPWO2017094733A1 (ja) 2015-11-30 2018-09-13 日産化学株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
DE102016100039A1 (de) 2016-01-04 2017-07-06 Universitätsklinikum Hamburg-Eppendorf (UKE) α6-Integrin bindendes DNA-Aptamer
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CA3011819A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US11061035B2 (en) 2016-01-22 2021-07-13 Purdue Research Foundation Charged mass labeling system
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
CN115850521A (zh) 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
WO2017139254A1 (en) 2016-02-08 2017-08-17 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11355328B2 (en) 2016-04-13 2022-06-07 Purdue Research Foundation Systems and methods for isolating a target ion in an ion trap using a dual frequency waveform
JP7118340B2 (ja) 2016-04-14 2022-08-16 フレッド ハッチンソン キャンサー センター 標的化核酸ナノ担体を使用して治療用細胞をプログラムするための組成物及び方法
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP3455378A1 (de) 2016-05-10 2019-03-20 Viasphere, LLC Zusammensetzungen und verfahren zur identifizierung, quantifizierung und/oder charakterisierung eines analyten
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
US11293017B2 (en) 2016-05-25 2022-04-05 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
EP3471757A1 (de) 2016-06-16 2019-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von entzündlichen darmerkrankungen wie etwa entzündlichen darmerkrankungen (ced) oder reizdarmsyndrom (rds)
EP3263706A1 (de) 2016-06-28 2018-01-03 Centre National De La Recherche Scientifique (Cnrs) Auf snat7 abzielende wirkstoffe zur behandlung von erkrankungen im zusammenhang mit der zellstoffwechselumprogrammierung
CN110312808A (zh) 2016-06-30 2019-10-08 拜欧亿思有限公司 双链核酸信号探针以及利用上述双链核酸信号探针的靶分子检测方法
EP3264092A1 (de) 2016-07-01 2018-01-03 Centogene AG Verwendung von lyso-gb1 als krankheitsassoziiertes ziel
JP7203613B2 (ja) 2016-07-01 2023-01-13 ソマロジック オペレーティング カンパニー インコーポレイテッド 修飾ヌクレオシドを含むオリゴヌクレオチド
EP3496739B1 (de) 2016-07-15 2021-04-28 Acceleron Pharma Inc. Zusammensetzungen enthaltend actriia-polypeptide zur verwendung bei der behandlung von pulmonaler hypertonie
US11041863B2 (en) 2016-07-21 2021-06-22 Retinal Solutions Llc Frizzled-4 mutation indicator of retinopathy and intrauterine growth restriction
EP3490582A4 (de) 2016-07-27 2020-04-01 Acceleron Pharma Inc. Verfahren und zusammensetzungen zur behandlung von myelofibrose
WO2018019537A1 (en) 2016-07-28 2018-02-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for obtaining aptamers
US9927441B1 (en) 2016-07-29 2018-03-27 X Development Llc Combinatorial methods for aptamer based proteomics
LT3494229T (lt) 2016-08-03 2024-02-12 Meiragtx Uk Ii Limited Ląstelėmis paremta didelio našumo aptamerų atranka
CN109963937A (zh) 2016-08-22 2019-07-02 日产化学株式会社 使用e-钙粘蛋白结合型核酸适配体的细胞支架材料
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
MX2019002473A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Métodos y composiciones para el direccionamiento de cánceres de células t.
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11730823B2 (en) 2016-10-03 2023-08-22 President And Fellows Of Harvard College Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
JP2019535651A (ja) 2016-10-04 2019-12-12 アスクレピクス セラピューティクス インコーポレイテッド Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法
EP3522934A4 (de) 2016-10-05 2020-04-15 Acceleron Pharma Inc. Zusammensetzungen und verfahren zur behandlung von nierenerkrankungen
US11016053B2 (en) 2016-10-05 2021-05-25 Abbott Laboratories Devices and methods for sample analysis
WO2018067872A1 (en) 2016-10-05 2018-04-12 Abbott Laboratories Devices and methods for sample analysis
EP3525782B1 (de) 2016-10-14 2023-12-06 CNS Biosciences, Inc. Behandlung von neuropathischen schmerzen bei personen mit rückenmarksverletzungen
CA3041451A1 (en) 2016-10-24 2018-05-03 Biois Co.,Ltd Tnf-.alpha.-binding aptamer, and therapeutic use for same
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
EP3315125A1 (de) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipidnanopartikelformulierung
US20200058369A1 (en) 2016-11-02 2020-02-20 Biois Co., Ltd. Quantitative Cluster Analysis Method Of Target Protein By Using Next-Generation Sequencing And Use Thereof
EP3332812A1 (de) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nukleinsäurebasierte anordnung und verwendung der anordnung in der krebstherapie
WO2018115083A1 (en) 2016-12-21 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3577133A1 (de) 2017-02-06 2019-12-11 Orionis Biosciences NV Gezielte chimäre proteine und verwendungen davon
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
CA3054294A1 (en) 2017-02-21 2018-08-30 Xuecui GUO Regulation of gene expression by aptamer-mediated accessibility of polyadenylation signals
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US20210145828A1 (en) 2017-06-29 2021-05-20 Rutgers, The State University Of New Jersey Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
EP3658168A4 (de) 2017-06-30 2021-07-14 Duke University Ordnung und unordnung als designprinzip für auf stimuli ansprechende biopolymernetzwerke
EP3428184A1 (de) 2017-07-09 2019-01-16 Universitätsklinikum Hamburg-Eppendorf Mittel zur behandlung von herz-kreislauf-erkrankung
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
CA3069933A1 (en) 2017-08-09 2019-02-14 The Procter & Gamble Company Aptamers for oral care applications
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US10934549B2 (en) 2017-08-18 2021-03-02 University Of Iowa Research Foundation Nucleic acid aptamers
EP3684471A1 (de) 2017-09-20 2020-07-29 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur modulation von autophagie
NL2019739B1 (en) 2017-10-16 2019-04-23 Academisch Ziekenhuis Leiden Means and methods for treating muscle degeneration
KR20200079534A (ko) 2017-11-09 2020-07-03 가부시키가이샤 리보믹 Adamts5에 대한 앱타머, 및 adamts5에 대한 앱타머의 용도
WO2019107532A1 (ja) 2017-11-30 2019-06-06 株式会社リボミック キマーゼに対するアプタマー及びその使用
US20200332296A1 (en) 2017-12-28 2020-10-22 Nuclixbio Aptamer template and method for preparing aptamer by using same
EP3521828A1 (de) 2018-01-31 2019-08-07 Centogene AG Verfahren zur diagnose eines hereditären angioödems
WO2019152979A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3762004B1 (de) 2018-03-05 2023-09-13 Klinikum rechts der Isar der Technischen Universität München Behandlung von tumoren durch eine kombination eines onkolytischen adenovirus und eines cdk4/6-inhibitors
US10481155B2 (en) 2018-03-09 2019-11-19 Somalogic, Inc. Proteomic assay using quantum sensors
WO2019175381A1 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765053A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigene peptide aus urocortin 3 und verwendungen davon zur diagnose und behandlung von typ-1-diabetes
EP3765065A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Von sekretogranin v abgeleitete, antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
WO2019202448A1 (en) 2018-04-16 2019-10-24 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
FR3081169B1 (fr) 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
CN112272775A (zh) 2018-06-04 2021-01-26 雅芳产品公司 用于鉴定和治疗衰老皮肤和皮肤病症的蛋白生物标志物
CN112384622A (zh) 2018-06-29 2021-02-19 宝洁公司 用于毛发护理应用的适配体
US11384357B2 (en) 2018-06-29 2022-07-12 The Procter And Gamble Company Aptamers for personal care applications
EP3829622A4 (de) 2018-08-02 2022-05-11 Duke University Doppel-agonisten-fusionsproteine
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP7379505B2 (ja) 2018-10-02 2023-11-14 ウェアオプティモ ピーティーワイ リミテッド 流体レベルの判定
EP3867383A1 (de) 2018-10-15 2021-08-25 Somalogic, Inc. Nukleinsäureverbindungen zur bindung von immunoglobulin g
WO2020079248A1 (en) 2018-10-19 2020-04-23 Neoneuro Early detection of precursor of alzheimer's disease
JP7332694B2 (ja) 2018-12-04 2023-08-23 エフ． ホフマン－ラ ロシュ アーゲー 細胞標的の空間指向性量子バーコード化
WO2020115223A1 (en) 2018-12-05 2020-06-11 Katholieke Universiteit Leuven S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
EP3897652A4 (de) 2018-12-20 2022-09-14 KSQ Therapeutics, Inc. Substituierte pyrazolopyrimidine und substituierte purine und ihre verwendung als inhibitoren der ubiquitin-specific-processing protease 1 (usp1)
US11883401B2 (en) 2019-01-08 2024-01-30 Duke University Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
US11319368B2 (en) 2019-01-21 2022-05-03 Singapore Health Services Pte Ltd. Treatment of hepatotoxicity with IL-11 antibody
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
EP3924379A4 (de) 2019-02-15 2022-12-21 Integral Molecular, Inc. Antikörper mit einer gemeinsamen leichten kette und deren verwendungen
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
US20220178940A1 (en) 2019-03-22 2022-06-09 Somalogic, Inc. Reducing Intersample Analyte Variability in Complex Biological Matrices
WO2020201521A1 (en) 2019-04-04 2020-10-08 Carmentix Pte. Ltd. Biomarker pairs of preterm birth
US20220170941A1 (en) 2019-04-04 2022-06-02 Carmentix Pte. Ltd. Biomarker Pairs of Preterm Birth
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP3956451A1 (de) 2019-04-16 2022-02-23 The Procter & Gamble Company Aptamere für geruchsunterdrückungsanwendungen
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
AU2020268619A1 (en) 2019-05-03 2021-12-16 National University Of Singapore Treatment and prevention of metabolic diseases
KR20220009948A (ko) 2019-05-17 2022-01-25 소마로직, 인크. 복합 생물학적 기질에서 시료 간 분석물의 변동성 제어
GB201908544D0 (en) 2019-06-14 2019-07-31 Nat Univ Singapore Treatment and prevention of disease mediated by wwp2
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
KR102113078B1 (ko) 2019-07-05 2020-05-20 광주과학기술원 압타머의 선별 방법
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021019196A1 (en) 2019-07-31 2021-02-04 University Of Dundee Analyte biosensing
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021026403A1 (en) 2019-08-07 2021-02-11 Abbott Laboratories Methods for detecting assay interferents and increasing dynamic range
JP2022543618A (ja) 2019-08-07 2022-10-13 アボット・ラボラトリーズ 多重化のための化学発光化合物
CA3151482A1 (en) 2019-09-03 2021-03-11 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
JP2022547885A (ja) 2019-09-05 2022-11-16 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン 腫瘍溶解性アデノウイルスと、ｃｄｋ４／６阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置
US20220333113A1 (en) 2019-10-16 2022-10-20 Somalogic Operating Co., Inc. Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein
BR112022011803A2 (pt) 2019-12-20 2022-08-30 Curevac Ag Nanopartículas de lipídio para entrega de ácidos nucleicos
US20230048910A1 (en) 2020-01-10 2023-02-16 Somalogic Operating Co., Inc. Methods of Determining Impaired Glucose Tolerance
BR112022015303A2 (pt) 2020-02-10 2022-09-27 Somalogic Operating Co Inc Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
WO2021183512A1 (en) 2020-03-10 2021-09-16 Abbott Laboratories Method for droplet loading into nanowells
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
GB2594094A (en) 2020-04-17 2021-10-20 Pockit Diagnostics Ltd Method for diagnosing stroke caused by large vessel occlusion
CN115997020A (zh) 2020-05-07 2023-04-21 因特欧力多公司 新的核酸配体及其鉴定方法
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
AU2021291555A1 (en) 2020-06-17 2023-02-02 Ribomic Inc. Aptamer for IL-21 and use thereof
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
US11859187B2 (en) 2020-06-25 2024-01-02 The Procter & Gamble Company Aptamers for personal health care applications
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
EP4200250A1 (de) 2020-08-18 2023-06-28 Regenacellx.SL Zusammensetzungen und verfahren zum nachweis von sars-cov-2-spike-protein
US20230338574A1 (en) 2020-09-02 2023-10-26 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same
US20230374492A1 (en) 2020-10-07 2023-11-23 Centre National De La Recherche Scientifique (Cnrs) Process for selection of aptamers, riboswitches and desoxyriboswitches
EP4232825A2 (de) 2020-10-20 2023-08-30 SomaLogic Operating Co., Inc. Risikovorhersage für kardiovaskuläre ereignisse
EP4236958A1 (de) 2020-10-30 2023-09-06 KSQ Therapeutics, Inc. Feste formen von substituierten pyrazolopyrimidinen und verwendungen davon
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN112779320B (zh) * 2020-12-04 2023-07-14 深圳市易基因科技有限公司 多区域dna甲基化检测探针设计及其检测方法
KR20230119130A (ko) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법
KR20230123501A (ko) 2020-12-18 2023-08-23 탁시스 바이오 가부시키가이샤 Dna 앱타머의 스크리닝에 사용 가능한 신규 인공 염기를갖는 디옥시리보뉴클레오시드, 디옥시리보뉴클레오티드, 및 이를 함유하는 핵산
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
EP4284513A1 (de) 2021-01-26 2023-12-06 Universite Brest Bretagne Occidentale Neuartige stim1-spleissvarianten und verwendungen davon
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
KR20230170688A (ko) 2021-04-13 2023-12-19 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 변형된 뉴클레오사이드
CA3214181A1 (en) 2021-04-14 2022-10-20 Amy D. GELINAS Nucleic acid compounds that bind coronavirus proteins
WO2022232308A1 (en) 2021-04-27 2022-11-03 Singular Genomics Systems, Inc. High density sequencing and multiplexed priming
WO2022266031A2 (en) 2021-06-15 2022-12-22 Somalogic Operating Co., Inc. Renal insufficiency prediction and uses thereof
WO2023278502A1 (en) 2021-06-30 2023-01-05 Somalogic Operating Co., Inc. Renal health determination and uses thereof
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
KR20230022813A (ko) 2021-08-06 2023-02-16 인터올리고 주식회사 비천연 핵산 리간드 및 이의 용도, 및 이를 유효성분으로 포함하는 암의 치료를 위한 약학적 조성물
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023039522A1 (en) 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
CA3233512A1 (en) 2021-10-06 2023-04-13 Alexander Muik Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
WO2023059854A1 (en) 2021-10-07 2023-04-13 Somalogic Operating Co., Inc. Lung cancer prediction and uses thereof
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023066881A1 (en) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition of map3k15 for treating and preventing diabetes
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023114800A1 (en) 2021-12-14 2023-06-22 The Procter & Gamble Company Aptamers for personal health care applications
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
WO2023141248A1 (en) 2022-01-21 2023-07-27 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection
WO2023183873A1 (en) 2022-03-24 2023-09-28 Mensura Health Inc. Aptamers and uses thereof
WO2023211773A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211771A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211770A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211769A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023235858A1 (en) 2022-06-03 2023-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered cell-penetrating antiviral compound
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024015486A1 (en) 2022-07-14 2024-01-18 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2024015485A1 (en) 2022-07-14 2024-01-18 Somalogic Operating Co., Inc. Methods of assessing dementia risk
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024030432A1 (en) 2022-08-01 2024-02-08 Gensaic, Inc. Therapeutic phage-derived particles
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024064322A2 (en) 2022-09-23 2024-03-28 Somalogic Operating Co., Inc. Methods of assessing tobacco use status
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016575A1 (de) * 1980-04-30 1981-11-05 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur immunologischen bestimmung von enzymen, mittel zur durchfuehrung des verfahrens und seine verwandung
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183661B (en) * 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4942122A (en) * 1987-02-24 1990-07-17 Research Education Institute, Inc. Aids prognosis test detecting the presence of antibodies inhibiting HIV reverse transcriptase
US4935363A (en) * 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
US5070010A (en) * 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
EP0523140A4 (en) * 1990-03-21 1993-06-16 Isis Pharmaceuticals, Inc. Reagents and methods for modulating gene expression through rna mimicry
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
JPH06503715A (ja) * 1990-09-21 1994-04-28 フレッド ハッチンソン キャンサー リサーチ センター タンパク質配列特異的オリゴヌクレオチド配列
JPH06508022A (ja) * 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
IE920561A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
DK2080813T3 (da) * 1995-06-07 2011-03-28 Gilead Sciences Inc Nukleinsyreligander, som binder til og inhiberer DNA-polymeraser
US5861246A (en) * 1996-01-24 1999-01-19 Yale University Multiple selection process for binding sites of DNA-binding proteins
US5859227A (en) * 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins

Also Published As

Publication number Publication date
CA2084987C (en) 2007-02-13
DE69128350D1 (de) 1998-01-15
EP0786469A3 (de) 1997-08-06
EP0533838A4 (en) 1993-05-26
US6933116B2 (en) 2005-08-23
EP0786469B1 (de) 2006-03-01
AU663053B2 (en) 1995-09-28
WO1991019813A1 (en) 1991-12-26
DE69128350T2 (de) 1998-03-26
EP1493825A2 (de) 2005-01-05
NZ238492A (en) 1993-07-27
EP0786469A2 (de) 1997-07-30
DK0533838T3 (da) 1998-02-23
DK0786469T3 (da) 2006-07-10
EP0533838B1 (de) 1997-12-03
ES2110444T3 (es) 1998-02-16
US5696249A (en) 1997-12-09
US20030198989A1 (en) 2003-10-23
EP1493825A3 (de) 2005-02-09
GR3025594T3 (en) 1998-03-31
JP2007195560A (ja) 2007-08-09
US6110900A (en) 2000-08-29
IL112141A (en) 1998-04-05
JP2007195559A (ja) 2007-08-09
EP1695978A1 (de) 2006-08-30
IE911979A1 (en) 1991-12-18
IL98456A0 (en) 1992-07-15
US5670637A (en) 1997-09-23
US5843653A (en) 1998-12-01
DE69133513T2 (de) 2006-09-21
RU2198931C2 (ru) 2003-02-20
ATE318832T1 (de) 2006-03-15
IE980162A1 (en) 2000-02-23
AU8206191A (en) 1992-01-07
KR970002255B1 (ko) 1997-02-26
US20030157487A1 (en) 2003-08-21
EP0533838A1 (de) 1993-03-31
JP2763958B2 (ja) 1998-06-11
JPH05507413A (ja) 1993-10-28
US5475096A (en) 1995-12-12
JP4276272B2 (ja) 2009-06-10
DE69133513D1 (de) 2006-04-27
IL98456A (en) 1997-03-18
ES2259800T3 (es) 2006-10-16
JPH08252100A (ja) 1996-10-01
US6331398B1 (en) 2001-12-18
CA2084987A1 (en) 1991-12-12

Similar Documents

Publication Publication Date Title
DK0533838T3 (da) Nukleinsyreligander
RU92016539A (ru) Способ идентификации лигандов, способ получения антитела, способ отбора нуклеиновой кислоты, способ получения смеси нуклеиновых кислот, смесь нуклеиновых кислот, антитело
ATE274520T1 (de) Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
ATA14789A (de) Gewinnung von amphiregulin durch gentechnische verfahren
DE3860768D1 (de) Verfahren zur herstellung von hochduktilem tantal-halbzeug.
DE3873094T2 (de) Verfahren zur aufbereitung von gas.
DE3860106D1 (de) Verfahren zur brikettierung von kohle.
DE3862647D1 (de) Verfahren zur durchmischung von schuettguetern.
DE3484405D1 (de) Verfahren zur epoxidierung von olefinisch ungesaettigten verbindungen.
DE3874510D1 (de) Verfahren zur stabilisierung von hydroisomeraten.
DE3672242D1 (de) Verfahren zur dimerisierung von ethylenisch ungesaettigten verbindungen.
DE3874667D1 (de) Verfahren zur reinigung von methacrylsaeure.
DE3871001D1 (de) Verfahren zur reinigung von phenol.
DE3863549D1 (de) Verfahren zur beseitigung von abfaellen durch verbrennen mit sauerstoff.
DE59105908D1 (de) Verfahren zur Herstellung von Bis(hydroxymethyl)phosphinaten.
DK0415557T3 (da) Separation af antimetalchelat-antistoffer
DE3677663D1 (de) Verfahren zur nitrierung von phenolverbindungen.
DE68909515T2 (de) Durch Antikörper und Liganden bewirkte Zielrichtung von Differentiationsinduktoren auf Tumorzellen.
DE3667287D1 (de) Verfahren zur herstellung von bis(dialkylphenyl)pentaerythritoldiphosphiten.
DE3879351D1 (de) Verfahren zur herstellung von bis(4-amino-phenyl)hexafluoropropan.
DE3775849D1 (de) Verfahren zur produktion von eisen-ii-sulfid.
DE3882674D1 (de) Verfahren zur bindung von biologischen reagenzien an poroese traeger.
ATE31486T1 (de) Verfahren zur mehrstufigen mischkondensation von daempfen.
DE69009772T2 (de) Verfahren zur produktion von organischen fluorierten verbindungen.
DE3869627D1 (de) Verfahren zur herstellung von carboxylierten amid-bindemitteln.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee